Coherus Divests UDENYCA Franchise to Intas in $558.4M Deal to Fund Immuno-Oncology Expansion

Redwood City, CA, December 3, 2024 (Globe Newswire) -- Coherus is selling its UDENYCA franchise to Intas Pharmaceuticals for up to $558.4 million, using proceeds to repay debt and focus on its immuno-oncology portfolio. The company aims to advance key therapies, including LOQTORZI®, its FDA-approved PD-1 inhibitor. This move strengthens Coherus’ financial position and accelerates its immuno-oncology strategy.

Read full article here.